The reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines.
Heyse
J F
JF
Kaplan
K M
KM
D001426:Bacterial Proteins / Q000276:immunology; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D012107:Research Design; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology
D001426:Bacterial Proteins; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D017325:Hepatitis B Vaccines; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic; C061963:HibTITER protein, Haemophilus influenzae